Back to Search
Start Over
Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine
- Publication Year :
- 2019
- Publisher :
- UK : Churchill Livingstone, 2019.
-
Abstract
- Objectives: Common therapies for HER2-positive advanced breast cancer (ABC) are associated with heterogeneity in prognosis and treatment benefit. Prognostic models of survival outcomes with ado-trastuzumab-emtansine (T-DM1) have not been evaluated.Material and methods: A pre-treatment prognostic model for overall survival (OS) and progression-free survival (PFS) based on clinicopathological factors was developed for HER2-positive ABC patients initiating second-line and later T-DM1 using data from the randomised clinical trials EMILIA and TH3RESA(n ¼ 893). Pre-treatment prognostic groups were identified via recursive partitioning analysis.Results: The most significant OS/PFS pre-treatment risk predictors were metastatic sites count (( ≤ 2versus > 2) and ECOG performance-status (0 versus ≥ 1) (P < 0.05). Based on these two factors, patient scan be characterised as one of three prognostic groups (good ¼ 0 factors; intermediate ¼ 1 factor;poor ¼ 2 factors). The prognostic groups were identified as significantly associated with OS (P < 0.001)and PFS (P < 0.001). Median OS for the good, intermediate and poor prognostic groups were 40 (95%CI:36e48), 25 (23e30) and 16 (14e19) months, respectively, and median PFS was 12 (10e15), 8 (7e9) and 6(4e7) months.Conclusion: Pre-treatment prognostic groups with significant differences in OS and PFS for HER2-positive ABC patients initiating second-line and later T-DM1 were identified. For HER2-positive ABC patients considering initiating second-line and later T-DM1, the prognostic groups enable more personalized expectations of disease control, survival and absolute treatment benefit. Refereed/Peer-reviewed
- Subjects :
- Adult
Oncology
medicine.medical_specialty
Ado-trastuzumab emtansine
Receptor, ErbB-2
Advanced breast
Breast Neoplasms
Recursive partitioning
Ado-Trastuzumab Emtansine
survival
Disease-Free Survival
03 medical and health sciences
Antineoplastic Agents, Immunological
0302 clinical medicine
Risk Factors
Internal medicine
medicine
Overall survival
Humans
prognostic model
030212 general & internal medicine
neoplasms
Randomized Controlled Trials as Topic
advanced breast cancer
business.industry
Cancer
General Medicine
Middle Aged
Prognosis
medicine.disease
Disease control
Progression-Free Survival
Clinical trial
Treatment Outcome
030220 oncology & carcinogenesis
ado-trastuzumab emtansine
Prognostic model
Female
Surgery
progression
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....dd0b17e86fa3281204922f12207c6377